Name: Latest research reports of Indegene Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Indegene Ltd.
Rating: 3
Author: Motilal Oswal

Indegene Ltd.

NSE: INDGN | BSE: 544172 | ISIN: INE065X01017 | Industry: Healthcare Services
| Mid-range Performer

464.6500 -5.60 (-1.19%)

NSE Apr 07, 2026 15:31 PM

26.58% Fall from 52W High

Volume: 658.8K

Indegene Ltd.

31 Jan 2026

464.65

-1.19%

Acquisition drives growth with steady organic performance

Neutral: Indegene Ltd.

Motilal Oswal

Indegene’s 3QFY26 USD revenue rose 15.1% QoQ, aided by the BioPharm acquisition, while organic USD revenue growth stood at 4% QoQ (below our estimate).

Indegene Ltd.'s price crossed below 50Day SMA today